{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:24:46Z","timestamp":1768454686270,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Benign intracranial hypertension, i.e. increased intracranial pressure, is a well-known rare adverse effect of tetracyclines, but its association with glycylcyclines (tetracycline-like antibiotics) was not confirmed. To investigate whether there are signals in an adverse events database for increased intracranial pressure after using tigecycline and eravacycline, and to compare it with probably existing signals for tetracyclines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This secondary research was based on the FDA Adverse Event Reporting System (FAERS) Database. Disproportionality analysis was conducted and the following disproportionality indices were calculated: reporting odds ratios (ROR), Yule\u2019s Q, proportional reporting ratio (PRR) and the information component (IC) for \u2018intracranial pressure increased\u2019 and \u2018pseudotumor cerebri\u2019 adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant signals for adverse event \u2018intracranial pressure increased\u2019 were found for doxycycline (ROR\u200a\u00b1\u200a95%CI\u200a=\u200a27.19\u200a\u00b1\u200a4.95), tetracycline (ROR\u200a\u00b1\u200a95%CI\u200a=\u200a79.29\u200a\u00b1\u200a24.64) and minocycline (ROR\u200a\u00b1\u200a95%CI\u200a=\u200a59.53\u200a\u00b1\u200a16.39). Signals for omadacycline and sarecycline were not found, primarily due to the small number of reports. In the database, there were no reports of increased intracranial pressure, pseudotumor cerebri or intracranial hypertension for both tigecycline and eravacycline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although structurally related to tetracyclines, glycylcyclines are not associated with increased intracranial pressure based on current pharmacovigilance data. This may warrant re-evaluation of SmPC warnings and supports safer use in patients with suspected intracranial hypertension when no better alternatives are available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf395","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:42:12Z","timestamp":1759837332000},"source":"Crossref","is-referenced-by-count":0,"title":["No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis"],"prefix":"10.1093","volume":"81","author":[{"given":"Slobodan M","family":"Jankovic","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac , Kragujevac ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojana","family":"Vujovic","sequence":"additional","affiliation":[{"name":"Clinics for Anesthesiology, Reanimation and Intensive Therapy, Clinical Center of Montenegro , Podgorica ,","place":["Montenegro"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison Rebecca","family":"Zamora Coronado","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Saltillo Unit, Autonomous University of Coahuila , Saltillo ,","place":["Mexico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Mendes Duarte","sequence":"additional","affiliation":[{"name":"Barretos School of Health Sciences\u2014Dr Paulo Prata , Barretos ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Pontes de Oliveira Ten\u00f3rio","sequence":"additional","affiliation":[{"name":"Course of Medicine, University Center CESMAC , Maceio ,","place":["Brasil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Rekik","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Sfax , University of Sfax, Sfax ,","place":["Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassine","family":"Ennouri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis ,","place":["Tunisia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2026011413264366200_dkaf395-B1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2146\/ajhp050487","article-title":"Tigecycline: a new glycylcycline antimicrobial agent","volume":"63","author":"Kasbekar","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"2026011413264366200_dkaf395-B2","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: the tetracyclines strike back","volume":"53","author":"Heaney","year":"2019","journal-title":"Ann Pharmacother"},{"key":"2026011413264366200_dkaf395-B3","author":"Pfizer Limited"},{"key":"2026011413264366200_dkaf395-B4","author":"PAION UK Ltd"},{"key":"2026011413264366200_dkaf395-B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/bmj.282.6257.19","article-title":"Tetracycline and benign intracranial hypertension: report of five cases","volume":"282","author":"Walters","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2026011413264366200_dkaf395-B6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archopht.125.8.1137","article-title":"Intracranial pressure returns to normal about a month after stopping tetracycline antibiotics","volume":"125","author":"Winn","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"2026011413264366200_dkaf395-B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajo.2020.07.037","article-title":"A comparison between the clinical features of pseudotumor cerebri secondary to tetracyclines and idiopathic intracranial hypertension","volume":"220","author":"Orme","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"2026011413264366200_dkaf395-B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3389\/fmicb.2017.00497","article-title":"Prescription patterns for tigecycline in severely ill patients for non-FDA approved indications in a developing country: a compromised outcome","volume":"8","author":"Moghnieh","year":"2017","journal-title":"Front Microbiol"},{"key":"2026011413264366200_dkaf395-B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clineuro.2018.06.008","article-title":"Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: results of the EGE study","volume":"172","author":"Sipahi","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"2026011413264366200_dkaf395-B10","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/jac\/dkac040","article-title":"Impact of drug safety warnings and antimicrobial stewardship programme implementation on tigecycline prescribing: a prospective quasi-experimental interrupted time series analysis","volume":"77","author":"Barrantes-Gonz\u00e1lez","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026011413264366200_dkaf395-B11","author":"U.S. Food and Drug Administration (FDA)"},{"key":"2026011413264366200_dkaf395-B12","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"2026011413264366200_dkaf395-B13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026011413264366200_dkaf395-B14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"2026011413264366200_dkaf395-B15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/17425255.2011.623126","article-title":"Pharmacokinetic and pharmacodynamic evaluation of tigecycline","volume":"7","author":"Giamarellou","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026011413264366200_dkaf395-B16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/00365548.2013.837957","article-title":"Cerebrospinal fluid penetration of tigecycline","volume":"46","author":"Pallotto","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"2026011413264366200_dkaf395-B17","doi-asserted-by":"publisher","first-page":"e00275-18","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits","volume":"62","author":"Petraitis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413264366200_dkaf395-B18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.2460\/ajvr.71.9.1062","article-title":"Pharmacokinetics and tissue distribution of minocycline hydrochloride in horses","volume":"71","author":"Nagata","year":"2010","journal-title":"Am J Vet Res"},{"key":"2026011413264366200_dkaf395-B19","doi-asserted-by":"publisher","first-page":"1033980","DOI":"10.3389\/fmed.2022.1033980","article-title":"Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity","volume":"9","author":"Grada","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026011413264366200_dkaf395-B20","author":"AMUB"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf395\/64952742\/dkaf395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf395\/64952742\/dkaf395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:26:47Z","timestamp":1768415207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf395\/8303491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf395","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,27]]},"article-number":"dkaf395"}}